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Introduction
Transcription is regulated by the recruitment of chromatin 
remodeling and histone modifying activities at gene regulatory 
elements such as promoters and enhancers. Histone modifiers 
include several regulatory factors such as histone acetyltransfer-
ases (HAT), histone deacetylases (HDAC), lysine methyltrans-
ferases (KMT), and lysine demethylases (KDM). It is generally 
accepted that the acetyl group neutralizes the positive charge 
of the side chain of the lysine residues within the histone tails 
thereby diminishing the interaction with the negatively charged 
DNA,1-3 allowing an open chromatin conformation and acces-
sibility to transcription factors. In addition, acetyl-lysines are 
recognized by small protein domains such as bromodomain.4 
Similarly, methyl groups on lysines serve as docking sites for 
small protein domains that stabilize protein-protein interactions 
between histones and effector proteins.4 Lysines can be mono, di, 
or trimethylated and the consequences are site and state-specific. 
For example, H3K9me1 (histone H3 monomethylated on lysine 
9), H3K4me3 (H3 trimethylated on lysine 4), and H3K36me3 
are generally found in the vicinity of active promoters, while 
H3K9me3 and H3K27me3 are usually found at transcriptionally 
silenced promoters.5
Although histone lysine methylation was discovered over four 
decades ago,6,7 the first histone lysine methyltransferase was only 
identified 36 years later.8 The latest human genome annotation 
reveals approximately 66 potential KMTs containing a SET cata-
lytic domain, a SET-like PR domain, or a 7-β-strand structure.9,10 
The role of lysine methylation in human pathologies is high-
lighted by the increasing number of KMTs involved in the etiol-
ogy of cancer,11,12 growth defects,13,14 and neurological disorders.15
The methyltransferase SETD6 was recently shown to mono-
methylate the histone H2A variant H2AZ on lysines 4 and 7 
(H2AZK4me1K7me1) and demonstrated to be essential for the 
maintenance of self-renewal in embryonic stem cell.16 SETD6 
was also found to methylate the RELA subunit of NFκB on 
lysine 310, thereby enhancing protein-protein interaction with 
the G9A-like methyltransferase EHMT1 (GLP) and resulting in 
transcriptional silencing of inflammation-regulated genes.17
Estrogen receptors have clear links to the etiology of breast 
cancer. Specifically, the estrogen receptor α (ERα or ESR1) is 
frequently overexpressed18 or mutated19 in breast carcinomas. The 
estrogen hormone binds to ERα, which activates transcription 
of estrogen-responsive genes20,21 leading to proliferation of mam-
mary cells.22 Anti-estrogens are used as chemotherapeutic agents 
to counteract the proliferative effects of estrogen. However, ERα- 
tumors do not respond to anti-estrogenic treatments and ERα+ 
tumors eventually become resistant to hormonal chemotherapies.
We have found that SETD6 associates with the NuRD com-
plex subunits MTA2 and HDAC1. Consequently, SETD6 silences 
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The lysine methyltransferase sETD6 modifies the histone variant h2aZ, a key component of nuclear receptor-depen-
dent transcription. herein, we report the identification of several factors that associate with sETD6 and are implicated in 
nuclear hormone receptor signaling. specifically, sETD6 associates with the estrogen receptor α (ERα), histone deacet-
ylase hDac1, metastasis protein MTa2, and the transcriptional co-activator TRRaP. Luciferase reporter assays identify 
sETD6 as a transcriptional repressor, in agreement with its association with hDac1 and MTa2. however, sETD6 behaves 
as a co-activator of several estrogen-responsive genes, such as PGR and TFF1. consistent with these results, silencing of 
sETD6 in several breast carcinoma cell lines induced cellular proliferation defects accompanied by enhanced expression 
of the cell cycle inhibitor CDKN1A and induction of apoptosis. herein, we have identified several chromatin proteins that 
associate with sETD6 and described sETD6 as an essential factor for nuclear receptor signaling and cellular proliferation.
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transcription of GAL4-dependent luciferase reporters. However, 
the expression of endogenous PGR and TFF1 estrogen-responsive 
genes is repressed upon silencing of SETD6. The silencing of 
SETD6 expression culminates in cellular proliferation defects, 
apoptosis, and enhanced expression of the cell cycle inhibitor 
CDKN1A. Herein, we identify novel SETD6-associated proteins 
and depict SETD6 as a transcriptional regulator involved in 
nuclear receptor signaling. Importantly, the silencing of SETD6 
induced proliferation defects independently of the status of ERα.
Results
SETD6 associates with chromatin proteins
SETD6 is composed of a SET catalytic domain, a substrate 
binding domain (SBD), and two putative LxxLL nuclear recep-
tor interaction motifs (Fig. 1A). The first LxxLL motif is bur-
ied deep within the SET domain (Fig. S1). However, the second 
LxxLL motif found at the carboxy terminus of SETD6 is at the 
surface of the enzyme (Fig. S1) and quite possibly accessible for 
protein-protein interactions with nuclear receptors. SETD6 is 
ubiquitinated within the SBD at lysine 441,23 suggesting that 
substrate specificity could be regulated by post-translational 
modifications.
Since little is known regarding SETD6 functions, we set out 
to identify SETD6-associated proteins. We have thus generated 
a stably-expressing FLAG-SETD6 cell line and a parental FLAG 
control cell line using the human osteosarcoma U2OS cell line. 
Those cells were transduced using pMSCV-FLAG (pMF) or 
pMF-SETD6 retroviral particles and then selected with puro-
mycin. SETD6-associated peptides were affinity purified using 
an α-FLAG matrix. Then, SETD6-associated proteins were 
essentially identified by previously described mass spectrometric 
methods.24,25 Interestingly, several 
SETD6-associated proteins identi-
fied have known biological functions 
related to nuclear hormone signaling 
(Fig. 1B). Particularly interesting, 
several peptides from the nucleosome 
remodeling deacetylase (NuRD) 
complex subunit, MTA2,26 were iden-
tified (Table S1). A complete list of 
SETD6-associated proteins can be 
found in the online supplementary 
material section (Table S2). We then 
validated the mass spectrometric data 
by immunoblotting. An immunopre-
cipitation of FLAG-SETD6 followed 
by immunoblotting validated the 
association of SETD6 with endog-
enous MTA2, TAF4, and TRRAP 
(Fig. 1C). Exogenous expression of 
FLAG-SETD6 was extremely low and 
could only be detected once immuno-
affinity purified (Fig. 1C).
SETD6 associates with an 
MTA2/HDAC1 complex
Since the NuRD complex contains other subunits such as 
HDAC1, we investigated the association of SETD6 with vari-
ous subunits of HDAC1-associated complexes. FLAG-tagged 
HDAC1 was co-expressed along with either YFP-tagged SETD6 
or ING2, a known subunit of the SIN3A/HDAC1 complex. 
Although the expression of YFP-SETD6 was lesser than YFP-
ING2, YFP-SETD6 co-immunoprecipitated with FLAG-
HDAC1 to a greater extent than ING2 (Fig. 2A). These results 
suggest that SETD6 is an authentic HDAC1-binding protein.
We then further characterized the SETD6/HDAC1 com-
plex. FLAG-SETD6 was expressed in the highly transfect-
able HEK293T cell line and immunoaffinity purified. The 
immunoprecipitates were analyzed with antibodies directed 
against known SIN3A/HDAC1 complex subunits. As shown 
above, SETD6 associated with endogenous TRRAP (Fig. 2B). 
However, SETD6 failed to associate with SAP30 (a subunit of 
the SIN3A complex), SIN3A, RBAP46 (a subunit shared by both 
SIN3A and NuRD complexes), and CHD3 (MI-2 a subunit of 
the NuRD complex) (data not shown). Although the expression 
of MTA2 and TRRAP at the mRNA level was mildly affected 
by the silencing of SETD6 (Fig. S2), the protein level remained 
unaffected (Fig. 2B).
Finally, since the NuRD complex is an important regula-
tor of ER-dependent transcription27,28 and SETD6 contains 2 
LxxLL nuclear receptor-binding motifs, we investigated the 
possible association between SETD6 and the nuclear receptor 
ERα. FLAG-tagged ERα was co-expressed in MCF7 cells with 
YFP-SETD6 or YFP-SET7 as a negative control. FLAG immu-
noprecipitates were analyzed by immunoblotting using an anti-
GFP antibody (recognizes wild-type GFP, but also destabilized 
EGFP variants, such as EYFP) and ERα was found to specifi-
cally associate with SETD6 (Fig. 2C). Then, FLAG-ERα and 
Figure 1. sETD6 associates with chromatin proteins. (A) scaled graphical representation of sETD6. sETD6 
contains a sET (su[var]3–9, Enhancer-of-zeste, Trithorax) domain, substrate binding domain (sBD), two 
LxxLL nuclear receptor binding motifs, and is ubiquitinated at lysine 441 (Ub). (B) Table highlighting the 
nuclear receptor signaling factors identified by mass spectrometry that associate with sETD6. a com-
plete detailed list of sETD6 associated proteins is available in the supplementary Table S2. (C) Validation 
of the mass spectrometric data by denaturing PaGE (sDs-PaGE) of α-FLaG M2-agarose immunoprecipi-
tates followed by immunoblotting against the indicated endogenously expressed proteins.
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YFP-SETD6 were co-expressed in MCF7 cells in the 
presence or absence of estradiol (E2). Interestingly, 
SETD6 association with ERα appeared to be 
enhanced in the presence of E2 (Fig. 2D). Finally, 
both LxxLL motifs found in SETD6 were converted 
to AxxAA and the YFP-SETD6
mLxxLL
 construct co-
expressed with FLAG-tagged ERα. Interestingly, the 
SETD6
mLxxLL
 mutant retained its ability to associate 
with ERα (Fig. S3).
SETD6 is a transcriptional regulator
To investigate the potential transcription regula-
tory activity of SETD6, we fused the methyltransfer-
ase to the DNA binding domain of GAL4 and used 
an heterologous GAL4-responsive luciferase reporter 
containing five GAL4 DNA-binding elements 
upstream of the SV40 promoter.29 In the absence 
of GAL4 DNA-binding elements in the reporter 
(G0), the SET domain alone (GAL4-SETD6
SET
) 
and the full-length protein (GAL4-SETD6
WT
) had 
only a minimal effect on the expression of luciferase 
from the reporter construct (Fig. 3A). However, in 
the presence of five GAL4 DNA-binding elements 
(G5), both GAL4-SETD6
SET
 and GAL4-SETD6
WT
 
repressed transcription of the luciferase reporter by 
about 50 percent (Fig. 3A). Moreover, both GAL4-
SETD6
SET
 and GAL4-SETD6
WT
 had a dose-respon-
sive transcriptional effect on the G5TKluciferase 
reporter (Fig. 3B). We then compared the transcrip-
tional repression activity of SETD6 to other KMTs, 
including the H3K27 methyltransferase EZH2 
as well as the H3K9 methyltransferases SETDB1 
and SUV39H2. Similarly to these KMTs involved 
in transcriptional silencing, SETD6 repressed the 
expression of the G5TKluciferase reporter (Fig. 3C). 
In addition, we compared SETD6 activity on the 
GAL4-responsive reporter to a known transcriptional 
activator, E2F1 (Fig. S4). The latter results validate 
our system by showing both silencing and activat-
ing responses. The GAL4-tagged constructs were 
expressed at equivalent level (Fig. 3).
SETD6 is a co-activator of estrogen-responsive 
genes
Since SETD6 associates with nuclear receptor 
signaling-associated factors and ERα, we investigated 
the expression of known estrogen-responsive genes by 
qPCR in control and SETD6-depleted breast carci-
noma cell lines. The expression of SETD6 was silenced using pre-
viously validated shRNAs delivered by lentiviral transduction16 
in human breast carcinoma MDA MB231 (ER-, PGR- p53mut), 
MCF7 (ER+, PGR+ p53wt), and T47D (ER+, PGR+ p53mut) cell 
lines. The expression of the progesterone receptor gene PGR 
decreased substantially in all cell lines tested in response to 
SETD6-depletion (Fig. 4A–C). In the TFF1-expressing MCF7 
cell line, the silencing of SETD6 also induced repression of this 
other estrogen-responsive gene (Fig. 4B). However, the expres-
sion of the estrogen-responsive gene TGFA remained unaltered 
in response to silencing of SETD6 expression in all three cell 
lines (Fig. 4A–C). The silencing of SETD6 expression was reca-
pitulated using siRNA and these also led to reduced expression 
of TFF1 in MCF7 cells without altering the expression of ESR1 
(Fig. S5).
We then investigated the expression of PGR and TFF1 in 
unstimulated (E2-) and estradiol (E2+) treated MCF7 cells. The 
induction of both genes was reduced by half in SETD6-silenced 
cells compared with control cells (Fig. 4D), further suggesting 
Figure 2. sETD6 associates with an MTa2/hDac1 complex. (A) McF7 cells were tran-
siently transfected with either YFP alone, YFP-ING2, or YFP-sETD6 along with either 
empty FLaG vector or FLaG-hDac1. The cells were lysed 48 h post-transfection and 
protein extracts applied on an α-FLaG M2-agarose matrix. The FLaG immunoprecipi-
tates and 1/10 input were then analyzed by sDs-PaGE and immunoblotting with α-GFP 
antibody. an asterisk (*) in the bottom input panel indicates the position of each YFP-
tagged proteins. The same asterisks were transposed in the IP panel to indicate that 
YFP on its own did not interact with hDac1. (B) hEK293T cells were transiently trans-
fected with either pcDNa3 GaL4-FLaG or GaL4-FLaG-sETD6. Protein extracts were 
immunoprecipitated as in panel A and then analyzed with the indicated antibodies. 
(C) McF7 cells were transiently transfected with either empty vector or with FLaG-ERα 
and either YFP-sETD6 or YFP-sET7. α-FLaG immunoprecipitates were analyzed using 
α-GFP antibody. (D) McF7 cells were transiently transfected with or without FLaG-ERα 
and YFP-sETD6. Estradiol (100nM) was added 44 h post-transfection and left for 4 h. 
The α-FLaG immunoprecipitates were analyzed with an α-GFP antibody
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that SETD6 is playing a role in the 
expression of estrogen-responsive genes.
SETD6 regulates proliferation of 
breast carcinoma cell lines
Nuclear receptor signaling generally 
regulates cellular proliferation. Moreover, 
activation of estrogen-responsive genes 
leads to increased proliferation of mam-
mary cells.22,30 Since SETD6 associates 
with ERα and nuclear receptor signaling 
factors, and regulates estrogen-respon-
sive genes, we investigated the impact of 
SETD6 silencing on cellular proliferation 
of human breast carcinoma cell lines. To 
address the potential role of SETD6 on 
proliferation, breast carcinoma cell lines 
were transduced with lentiviral particles 
that express shRNAs targeting SETD6. 
Loss of SETD6 expression led to prolif-
eration defects as detected by a growth 
curve in the MCF7 cell line (Fig. S6). 
Specifically, all four SETD6-specific 
shRNA impaired proliferation rates when 
compared with the parental LKO con-
trol shRNA-expressing cells (Fig. S6). 
Proliferation rates were also assessed 
in a panel of human-derived breast 
carcinoma cell lines, including MDA 
MB231 (Fig. 5A), MCF7 (Fig. 5B), and 
T47D (Fig. 5C). Like MCF7 (Fig. 5B; 
Fig. S6), both ERα- MDA MB231 and 
ERα+ T47D cell lines showed prolifera-
tion defects upon silencing of SETD6. 
Strikingly, SETD6 shRNA sh7 and sh10 
cells displayed negligible growth over a 
period of 4 days (Fig. 5A–C). Moreover, 
silencing of SETD6 expression using 
siRNA instead of shRNA also reduced 
the proliferation of MCF7 and T47D cell 
lines (Fig. S7). These results demonstrate 
that SETD6 is required for normal cel-
lular proliferation of human mammary 
cells.
At late time points (72h and 96h) the 
number of cells had not changed appre-
ciably compared with earlier time points 
in SETD6-silenced samples, suggesting 
that prolonged loss of SETD6 expression 
disturbed cell cycle progression. We thus 
investigated the expression of estrogen-
responsive genes that are involved in cell 
cycle control. We observed that in MDA 
MB231, MCF7, and T47D cell lines 
the silencing of SETD6 systematically 
induced the expression of CDKN1A with 
a 6-fold increase of the cell cycle inhibitor 
Figure 3. sETD6 is a transcriptional regulator. (A) hEK293 cells were seeded at a density of 100,000 
cells per well of a 12-well plate and transfected the following day with 0.75μg of either pGL3 sV40luc 
(GaL4-unresponsive, i.e., G0) or pGL3 G5sV40luc (GaL4-responsive, i.e., G5) and 0.25μg GaL4DBD, 
GaL4-sETD6sET, or GaL4-sETD6WT. Values are expressed as relative luciferase units (R.L.U.) as mea-
sured 30 h post-transfection and error bars originate from the standard error of the mean from a 
representative experiment with each sample in quadruplets. *P values < 0.04. (B) as in panel A, but 
increasing amount (0.05 μg, 0.1 μg, 0.25 μg, and 0.5 μg) of GaL4-sETD6sET or GaL4-sETD6WT were 
transfected along with 0.5 μg reporter. *P values < 0.03 between the 0.0 5μg and 0.5 μg samples. 
(C) The indicated GaL4-tagged KMTs (0.25 μg) were transfected along with the G5sV40luc reporter 
(0.75 μg). *P values < 0.001. The expression level of each GaL4/FLaG-tagged constructs was assessed 
by denaturing PaGE of protein extracts followed by immunoblotting using the hRP-conjugated 
α-FLaG M2 or α-tubulin antibodies.
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946 Epigenetics Volume 9 Issue 7
in MDA MB231 (Fig. S8). Interestingly, the levels of cyclin D1 
(CCND1), GREB1, and VEGFA were lower in SETD6-silenced 
MCF7 cells (Fig. S8). Unlike the cell proliferation response to 
the silencing of SETD6, the transcriptional response seems to 
diverge between the cell lines, but CDKN1A was consistently 
upregulated in all cell lines.
To better understand the proliferation defects of SETD6-
depleted cells, we then investigated the cell cycle profile of 
SETD6-silenced MCF7 cells by flow cytometry. The analysis 
revealed an increase in the sub-G
1
 population from about 2% 
in control cells (LKO) to 20–35% in SETD6-silenced cells (sh7 
and sh10) (Fig. 5D), suggesting that decreased SETD6 expres-
sion induced apoptosis. Indeed, Annexin V staining, a marker 
of apoptosis, was enhanced by over 2-fold in SETD6-silenced 
MCF7 cells (Fig. 5E; Fig. S9).
Discussion
Herein, we have identified by mass spectrometry and vali-
dated by immunoblotting the association of the methyltransfer-
ase SETD6 with several endogenous proteins that are involved 
in nuclear hormone receptor signaling. In particular, we found 
that SETD6 associates with MTA2 (Metastasis associated 1 
family, member 2), a subunit of the NuRD complex26,31 that 
represses ER-dependent transcription.32,33 In addition, SETD6 
associates with the RNA-binding protein SLIRP, which inac-
tivates nuclear receptor-dependent transcription via an NCoR/
HDAC complex.34 Interestingly, SETD6 represses transcription 
when it is artificially tethered to a promoter, in agreement with its 
association with NuRD complex subunits HDAC1 and MTA2. 
However, we observed that in the context of estrogen-responsive 
genes, SETD6 appears to be required for the expression of the 
estrogen-responsive genes PGR and TFF1, thus acting as a co-
activator. In agreement with the repressive role of SETD6 in 
the GAL4 system and its association with HDAC1, the silenc-
ing of SETD6 led to increased expression of CDKN1A. Thus, it 
appears that depending on the transcriptional context, SETD6 
can act either as a repressor or as an activator. Previous genome-
wide studies of HDAC1 association with chromatin revealed 
that the deacetylase was bound along with RNA polymerase II 
to highly active promoters.35 In addition, the methyltransferase 
G9A, which methylates H3K9 and thus usually involved in tran-
scriptional repression, was recently depicted as a necessary factor 
for the expression of estrogen-responsive genes.36 These studies 
highlight that some chromatin factors can have both a positive 
and a negative role on the regulation of gene expression.
Although SETD6 could associate with MTA2 and HDAC1, 
it failed to associate with other NuRD complex subunits (CHD3 
and RBAP46) or with other SIN3A complex subunits (SAP30, 
SIN3A, and RBAP46). These results are not unexpected since 
the presence of SETD6 has never been detected in either bio-
chemically purified NuRD or SIN3A complexes. Thus, SETD6 
is either a substoichiometric component of the NuRD complex 
that could not be detected under previous experimental condi-
tions or SETD6 is simply not part of the NuRD complex and 
associates only with MTA2/HDAC1. Further investigations 
will be necessary to elucidate the role of the association between 
SETD6 and MTA2/HDAC1.
In addition to its association with a transcription repressive 
HDAC1 complex, SETD6 associates with the known gene co-
activators, LMNA, MGA, TAF4, and TRRAP. LMNA (Lamin 
A/C) associates with TIP60,37 a transcriptional co-activator of 
AR and ER.38,39 The association of SETD6 with LMNA may 
indicate a potential role for the methyltransferase in chromatin 
organization through the nuclear matrix. Both MGA and TAF4 
Figure 4. sETD6 is a co-activator of estrogen-responsive genes. (A) MDa MB231 cells were transduced with pLKO control shRNa or sETD6 shRNa (sh7) 
lentiviral particles. Total RNa was extracted 72 h post-transduction, reverse transcribed, and the expression of the indicated genes assessed by qPcR. 
The mRNa level from pLKO samples was set to 1. (B) as in panel A, but the experiment was conducted in McF7 cells. (C) as in panel A, but the experiment 
was conducted in T47D cells. The * indicate p-values < 0.0006. (D) McF7 were maintained in DMEM supplemented with charcoal-stripped serum prior to 
estradiol (E2) stimulation. The expression of GAPDH, PGR, SETD6, and TFF1 was assessed by qPcR. * Indicates P values < 0.004 and ** < 0.03.
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are subunits of the MLL1/WDR5 histone H3 lysine 4 methyl-
transferase complex.40 TRRAP is a co-activator of ER-dependent 
transcription and associates with ERα, GCN5, MAX, MYC, 
and p400.41,42 Thus, the transcriptional effects observed on estro-
gen-responsive PGR and TFF1 genes upon silencing of SETD6 
expression, may reflect the association of SETD6 with these 
co-activators.
TAF4 is one of the 14 TATA-binding protein (TBP)-associated 
factors (TAF) composing the TFIID complex. Essentially, tran-
scription is regulated by the binding of TBP to the TATA box 
and the nucleation of TAFs around TBP and the assembly of the 
pre-initiation complex (PIC), which is composed of RNA poly-
merase II and the general transcription factors TFIIA, TFIIB, 
TFIID, TFIIE, TFIIF, and TFIIH. TAF4 principal function 
appears to mediate interactions between TFIID and transcrip-
tional activators such as SP1, CREB1, retinoic acid receptors, 
JUN, and basic helix-loop-helix E proteins family, which binds 
E boxes (CANNTG).43 Alternative splice variants of TAF4 lack 
parts of the TAF homology domain, which mediates association 
with a variety of transcriptional factors. These TAF4 variants are 
differentially expressed in adult tissues, stem cells, and differen-
tiated cells, potentially leading to different tissue-specific gene 
expression patterns.44 To investigate how SETD6 regulates the 
expression of estrogen-responsive genes, we have performed chro-
matin immunoprecipitations of stably-expressed FLAG-SETD6 
and transiently overexpressed FLAG-SETD6 in MCF7 cells, but 
failed to detect its presence at the promoter of CDKN1A, PGR, 
or TFF1 (Fig. S10). Specifically, the association of SETD6 with 
chromatin was investigated at -1000 and -500 base pairs upstream 
of the transcriptional start site and at the transcriptional start site 
of CDKN1A, PGR, and TFF1. Although not evidence of absence, 
the absence of evidence for the presence of SETD6 at regulatory 
elements of CDKN1A, PGR, and TFF1 suggests that the silenc-
ing of SETD6 may affect indirectly the expression of those genes. 
The association of SETD6 with TAF4 may alter the activity of 
the TFIID complex with consequences on the transcription of 
genes such as CDKN1A, PGR, and TFF1, irrespectively of ER 
status.
The transformation and transcription domain-associated pro-
tein (TRRAP) was originally identified as an E2F1 and MYC-
associated protein.45 TRRAP also associates with the nuclear 
receptor ERα,46 and numerous histone acetyltransferase (HAT) 
complexes.47 Through its association with various HAT com-
plexes, TRRAP is involved in most DNA transaction processes, 
including transcription, replication, and repair. Interestingly, 
TRRAP–/– cells have impaired clonogenicity and proliferation,48 
similarly to SETD6-silenced mouse embryonic stem cells.16 
Recently, TRRAP was rediscovered in a screen to identify syn-
thetic interactions with MYC overexpression.49 Interestingly, 
SETD6 was originally found to associate with the ATPases 
RUVBL1 and RUVBL2,50 which are found in the human 
TIP60 histone acetyltransferase complex with TRRAP51 and 
involved in histone exchange of H2A variants.52 Thus, it could be 
hypothesized that the interaction between SETD6 and TRRAP, 
Figure 5. sETD6 regulates proliferation of breast carcinoma cell lines. (A) 50,000 MDa MB231 cells were transduced with pLKO control shRNa or sETD6 
shRNa (sh7 or sh10) lentiviral particles. The next day, the media was replaced and cells were counted (Time = 0 h). The cells were then counted again 
every 24 h. (B) as in panel a, but the experiment was conducted in McF7 cells. (C) as in panel A, but the experiment was conducted in T47D cells. Error 
bars originate from the standard error of the mean from a representative experiment with each sample counted four times. *Indicates P values < 0.0004. 
(D) cell cycle profile of McF7 control cells (LKO) and sETD6-silenced cells (sh7 and sh10). (E) as in panel D, but the McF7 cells were stained with annexin V.
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RUVBL1, or RUVBL2 may affect the deposition of H2AZ at 
promoters, including CDKN1A, PGR, and TFF1, to regulate the 
expression of estrogen-responsive genes irrespectively of ER sta-
tus. Indeed, silencing of SETD6 expression led to reduced level of 
the histone variant H2AZ and its methylated H2AZK7me1 form 
at the enhancer and promoter of TFF1 (Fig. S11).
The association of SETD6 with nuclear hormone recep-
tor signaling elements, ERα and MTA2 in particular, and the 
misregulation of estrogen-responsive genes in SETD6-depleted 
cells, prompted us to investigate the proliferation of those cells. 
All breast carcinoma cell lines tested stopped proliferating upon 
silencing the expression of SETD6. Importantly, both ER+ 
(MCF7 and T47D) and ER- (MDA MB231) cells were similarly 
affected by the silencing of SETD6 expression. In agreement 
with the cell blockage induced by the silencing of SETD6, all 
breast carcinoma cell lines investigated expressed increased levels 
of CDKN1A in response to reduced expression of SETD6. The 
effect of silencing SETD6 on proliferation was further investi-
gated in MCF7 and we observed an increase in sub-G
1
 popu-
lation and Annexin V staining, demonstrating that silencing of 
SETD6 induces apoptosis.
Finally, we have found that the regulation of estradiol-respon-
sive genes and cellular proliferation by SETD6 is independent of 
ERα status. Since ERα- tumors do not respond to anti-estrogenic 
treatments and ERα+ tumors eventually become resistant to hor-
monal chemotherapies, the regulation of ER signaling by SETD6 
independently of ERα status could potentially be exploited in 
future therapies. Thus, these results may have profound implica-
tion in the treatment of breast cancer patients.
Materials and Methods
Plasmids
The cDNA of SETD6 was purchased from OpenBiosystems 
and inserted in pMSCVpuro (Clontech), pcDNA3 GAL4-FLAG, 
and pcDNA3 YFP using restriction endonucleases (NEB). The 
FLAG-HDAC1 construct was described previously.16,53 The 
pLKO shRNA constructs were obtained from OpenBiosystems 
and described previously.16
Antibodies
α-TRRAP (ab73546), α-SIN3A (ab129087), α-SAP30 
(ab65559), TIP49A (ab133513), and α-RBAP46 (ab109285) 
were purchased from Abcam, α-FLAG M2-agarose and HRP-
conjugated α-FLAG M2 (A8592) were obtained from Sigma, 
and α-GFP (632375) from Clontech.
Immunoprecipitations
Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 
100 mM NaCl, 0.5% Triton X-100, 10% glycerol, and EDTA-
free protease inhibitors cocktail from Roche). Cleared lysates were 
inverted overnight at 4 °C with 10 μL of α-FLAG M2-agarose 
matrix (Sigma, A2220). The next day, the agarose beads were 
washed 4 times with 1mL of lysis buffer. Bound proteins were 
resolved by PAGE, transferred onto PVDF membranes, and ana-
lyzed by immunoblotting.
Growth curves
Cells were seeded at 50 000 cells per well of a 6-well plate 
for each time point. Approximately 6 h later, when the cells had 
adhered, the cells were transduced with shRNA-expressing len-
tiviral particles. The following day (time 0h), the media was 
changed and the first plate counted using an hematocymeter. 
The same counting procedure was repeated at 24 h, 48 h, and 
96 h, while an extra plate was kept for RNA extraction and gene 
expression analysis.
Flow cytometry analysis
Cell cycle was assessed by suspending MCF7 cells in a 
propidium iodide staining cocktail (0.8% Triton X-100, 
50 μg/mL propidium iodide, and 75 μg/mL RNase A) for 10 min 
at room temperature. Apoptosis was assessed by Annexin V Alexa 
Fluor488 and propidium iodide staining (Life Technologies, 
V13241). Stained cells were immediately injected into a BD 
FACSCalibur where 10 000 cells were evaluated per sample.
Mass spectrometric analysis
SETD6-bound proteins were immunoaffinity purified as 
described previously.25 Then, the SETD6-bound proteins were 
analyzed and identified by mass spectrometry as described 
elsewhere.24
Knockdowns and qPCR
Duplex siRNA were obtained from Dharmacon (cat. # 
MQ-014486–00–0005) and shRNA constructs were obtained 
from OpenBiosystems (RHS4533-NM_024860). Gene 
expression was assessed by qPCR on reverse transcribed total 
RNA. Briefly, total RNA was extracted using TRIzol reagent 
(Invitrogen, 15596–026), 2.5 μg of total RNA was reverse tran-
scribed using SuperScript VILO (Invitrogen, 11755–050), and 
qPCR performed using QuantiTect SYBR Green (QIAGEN, 
204143) on an ABI PRISM 7900HT Sequence Detection System 
(Applied Biosystems). Sequence of gene-specific primers used for 
qPCR are available in the supplementary section (Table S3).
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